ARYA Sciences Acquisition Corp IV (ARYD)

Etorro trading 970x250

About ARYA Sciences Acquisition Corp IV

ARYA Sciences Acquisition Corp IV focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 2020 and is based in New York, New York. Address: 51 Astor Place, 10th Floor, New York, NY, United States, 10003

ARYA Sciences Acquisition Corp IV News and around…

Latest news about ARYA Sciences Acquisition Corp IV (ARYD) common stock and company :

NOTICE - IMPORTANT SHAREHOLDER INVESTIGATION UPDATE: Brodsky & Smith Reminds Investors of Investigations Related to the Following Companies: ARYA Sciences Acquisition Corp IV (NASDAQ:ARYD), Poema Global Holdings Corp. (NASDAQ:PPGH), VPC Impact Acquisition Holdings III, Inc. (NYSE:VPCC)
06 Oct, 2021 Yahoo! Finance

BALA CYNWYD, PA / ACCESSWIRE / October 6, 2021 / Brodsky & Smith reminds investors of investigations it is conducting regarding the following companies for possible breaches of fiduciary duty and other violations of federal and state law with respect to proposed acquisition transactions. If you own shares of any of the below-referenced stocks and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will,

Moore Kuehn Encourages NOTV, ARYD, XLRN, and TGP Investors to Contact Law Firm
06 Oct, 2021 Yahoo! Finance

NEW YORK, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies: Inotiv, Inc. (NASDAQ: NOTV) Inotiv has agreed to merge with Envigo RMS Holding Corp. Under the p

The Week In SPAC News - Sunday, Oct. 3
03 Oct, 2021 FinancialContent

In SPAC news this week, Amicus Therapeutics announced its intent to sell its gene therapy unit to ARYA Sciences Acquisition Corp IV, a SPAC sponsored by Perceptive Advisors.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of ARYA Sciences Acquisition Corp. IV Merger
01 Oct, 2021 Yahoo! Finance

WILMINGTON, Del., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating ARYA Sciences Acquisition Corp. IV (“ARYA”) (NASDAQ CM: ARYD) regarding possible breaches of fiduciary duties and other violations of law related to ARYA’s agreement to merger with Amicus Therapeutics. To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-arya-sciences-acquisition-corp-iv. You may also contact Seth D. Rigrodsky or Gina M. Serra cost a

Amicus stock is up 5%, the day after announcing plans to sell its gene therapy business
30 Sep, 2021 Yahoo! Finance

Shares of Amicus Therapeutics Inc. were up 5.6% in premarket trading on Thursday, the day after the company announced a deal to sell its gene therapy business to ARYA Sciences Acquisition Corp IV , a special purpose acquisition company sponsored by Perceptive Advisors. Amicus will have a 36% stake in the new company, which will be called Caritas Therapeutics Inc. It will retain commercialization rights to the Fabry and Pompe gene therapy programs. Amicus chair and CEO John Crowley will become ch

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of ARYA Sciences Acquisition Corp IV (Nasdaq - ARYD)
29 Sep, 2021 Yahoo! Finance

("Amicus") (NASDAQ:FOLD), and result in Amicus' gene therapy business becoming Caritas Therapeutics, Inc., ("Caritas"), which will be a publicly-listed company.

Perceptive Advisors-Backed SPAC To Acquire Amicus's Gene Therapy Business
29 Sep, 2021 FinancialContent

Amicus Therapeutics Inc(NASDAQ: FOLD) hasagreed to spin off its gene therapy businesstoSciences Acquisition ...

The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
29 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA ...

Amicus Therapeutics and ARYA Sciences Acquisition Corp IV Announce Formation of a Next-Generation Genetic Medicine Company: “Caritas Therapeutics”
29 Sep, 2021 FinancialContent

ARYA Sciences Acquisition Corp IV (ARYD) is a NASDAQ Common Stock listed in , ,

970x250